11,001 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,001 shares of the biopharmaceutical company’s stock, valued at approximately $30,260,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ALNY. Allspring Global Investments Holdings LLC raised its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Maryland State Retirement & Pension System increased its stake in Alnylam Pharmaceuticals by 4.1% in the 1st quarter. Maryland State Retirement & Pension System now owns 9,836 shares of the biopharmaceutical company’s stock valued at $1,441,000 after buying an additional 385 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Alnylam Pharmaceuticals by 32.3% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 1,365 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Alnylam Pharmaceuticals by 63.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,415 shares of the biopharmaceutical company’s stock valued at $9,328,000 after buying an additional 24,228 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in Alnylam Pharmaceuticals by 47.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company’s stock valued at $415,000 after buying an additional 892 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Raymond James increased their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Scotiabank began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $305.00 target price for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $290.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock valued at $13,595,460 in the last three months. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $286.91 on Tuesday. The firm has a fifty day moving average price of $274.68 and a two-hundred day moving average price of $223.34. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a market cap of $36.29 billion, a price-to-earnings ratio of -107.06 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the previous year, the business earned ($2.21) earnings per share. The firm’s revenue for the quarter was up 107.0% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.